Cancer Stem Cell & Oncology Research

Xu Chen has a Masters of science from the College of St. Scholastica up in Northern Minnesota, USA. She is currently working on her PsyD through University of the Rockies.

Cancer, Cancer in Women, Thyroid Cancer

Dr. Wassil Nowicky, Dipl. Ing., Dr. techn., DDDr. h. c., Director of Nowicky Pharma and President of the Ukrainian Anti-Cancer Institute (Vienna, Austria). Has finished his study at the Radiotechnical Faculty of the Technical University of Lviv (Ukraine) with the end of 1955 with graduation to Diplomingeniueur in 1960 which title was nostrificated in Austria in 1975. Dr. Wassil Nowicky became the very first scientist in the development of the anticancer protonic therapy and is the inventor of the preparation against cancer with a selective effect on basis of celandine alkaloids NSC-631570. He used the factor that cancer cells are more negative charged than normal cells and invented the Celandine alkaloid with a positive charge thanks to which it accumulates in cancer cells very fast. Author of over 300 scientific articles dedicated to cancer research. Dr. Wassil Nowicky is a real member of the New York Academy of Sciences, member of the European Union for applied immunology and of the American Association for scientific progress, honorary doctor of the Janka Kupala University in Hrodno, doctor honoris causa of the Open international university on complex medicine in Colombo, honorary member of the Austrian Society of a name od Albert Schweizer. He has received the award for merits of National guild of pharmasists of America. the award of Austrian Society of sanitary, hygiene and public health services and others.

Dendritic cells are immune cells that act as messengers between the innate and adaptive immunity. Their main functions is to process antigen material and present it on the surface to other cells of the immune system, thus functioning as antigen‐presenting cells and are seen as the most potent population executing this function. In the experiments with the mononuclears from the peripheric blood of healthy persons the effect of the anti-cancer preparation NSC-631570 (Ukraine) on the phenotypic and functional properties of dendritic cells was studied. The most prominent induction of the expression of the cell surface molecules CD86 and HLADR was achieved with NSC-631570 at the lowest and highest concentration, 0.6 μg/mL and 10 μg/mL, respectively. Lipopolysaccharide as standard comparative agent induced similar increase of the cell surface receptors. The proliferation index of the incubated lymphocytes was used as the indicator of the dendritic cells activity. After addition of NSC631570 to the incubated dendritic cells, the lymphocyte proliferation index increased from 22.6% up to 32.30% at 0.6 μg/mL or 29.34% at 10 μg/mL, respectively. These values are similar to the one of 31.82%, i.e. proliferation index achieved at the incubation of lymphocytes with the phytohemagglutinin. The authors concluded dendritic cells incubated with NSC-631570 are strong stimulators of the lymphocyte proliferation. They postulate also NSC-631570 can take an important part in the immune therapy of cancer.

Dr. Elizabeth Rufus professor the Vellore Institute of Technology, India.

Sensors and Biomedical Technology

James E. Trosko completed his PhD at the age of 25 years from Michigan State University and spent 3 years as a postdoctoral fellow at Oak Ridge National Laboratory under Drs. Ernest Chu; Dr. Sheldon Wolff and Dr. Richard Setlow. After joining Michigan State University, he worked with Dr. Barnett Rosenberg on the characterization of the anti-cancer drug, Cis-platin. He obtained an NCI- Career Development award; spent one year at the McArdle Lab for Cancer Research at the University of Wisconsin under Dr. Van R. Potter. Later he was Chief of Research at the Radiation Effects Research Foundation for two years in Hiroshima and Nagasaki, Japan. He spent 2 years at Seoul National University as a Korean World Class University Professor. He also spent one year at the ARNAS-Civico-Regional Cancer Hospital in Palermo, Sicily. He is currently an MSU-Distinguished Emeritus Professor. He has published more than 450 papers.

Dr. Trosko's laboratory pioneered in the research on DNA repair in cells of normal humans and those of the skin cancer-prone, xeroderma pigmentosum. He also was the first to discover that epigenetic tumor promoters inhibited gap junctional inter cellular communication. His lab also was the first to isolate human adult organ specific stem cells (kidney-1987; breast 1995). He demonstrated that these human breast stem cells were the target cells for producing breast cancer stem cells. Later he proposed these human organ-specific adult stem cells be used to screen for new drugs and toxicants when grown in 3-dimensional in vitro cultures. Lastly, he has proposed that the mechanism underlying the Barker hypothesis was the increased or decreased number of organ-specific stem cells during early development.

Rusudan Sujashvili, Doctor of Biology, Full Professor, School of Medicine, New Vision University is a Chief scientist and a group leader for Cellular Biophysics at the Department of Biophysics, Iv. Beritashvili Center of Experimental Biomedicine. She obtained her Ph.D. degree from Iv. Javakhishvili Tbilisi State University in 2000. Her projects have been granted from Shota Rustaveli National Science Foundation in 2010-2012 and 2016-2019. Goal of her research group is to study the advantages of extracellular ubiquitin in regulation of molecular and cellular pathological changes implemented by genotoxic agents (ionizing radiation, chemo preventive drugs). Rusudan Sujashvili has published about 50 scientific works in recent years.

Advantages of extracellular ubiquitin in regulation of molecular and cellular pathological changes implemented by genotoxic agents (ionizing radiation, chemo preventive drugs)

Irine Ioramashvili MD, Physics, Specialization Biophysics, holds position of a Researcher in a group of Cellular Biophysics at the Department of Biophysics, Iv. Beritashvili Center of Experimental Biomedicine. She obtained her M.Sc degree after graduating from Iv. Javakhishvili Tbilisi State University in 2002. Participated in research projects granted from CRDF Global, with funding from the U.S. Defense Threat Reduction Agency (DTRA) in 2015-2016 and Shota Rustaveli National Science Foundation in 2016-2019. Irine Ioramashvili has published 12 scientific works in recent years.

Physics, Biophysics, Cellular Biophysics

Dr. Jing Wang is an INSERM researcher at the Institute of Neuroscience at the University of Montpellier (France) where she currently leads the team Degeneration and Therapies (http://www.inmfrance.com/inm/hearing/34-2- 2-molecular-basis-of-age-related-hearing-loss). Her work focuses on the study of mechanisms that trigger hearing loss associated with aging, as well as the development of therapies that reverse this loss.

In recent years, with the improvement of cancer survival through more effective treatment, the emphasis has been in trying to minimize the side effects caused by chemo- and radiotherapy, to ensure that patients have the best quality of life throughout their cancer journey. The tumour suppressor p53 is widely implicated in a broad range of cancers. Indeed, p53 is either mutated or inactivated in the majority of cancers. Abundant evidence indicates that toxicity caused by DNA-damaging anticancer therapies in normal tissues is also mainly mediated by p53. p53 accumulates in the cells shortly after anticancer challenges and acts as a nuclear transcription factor that modulates the expression of numerous p53-responsive genes (e.g. p21Waf1, 14-3-3-σ, Mdm2, cyclin G, Bax). This initiates a cascade of events leading to massive programmed cell death in specific normal tissues during the systemic genotoxic stress associated with chemo- and radiotherapies. This makes p53 a target for therapeutic suppression: an approach to reduce side effects associated with treatment of p53-deficient cancers. Here I summarise the role of p53 and the possibilities of its manipulation to improve side effects during active treatment through survivorship.

Dr. Alain Moreau is Full Professor in the Faculty of Dentistry and the Faculty of Medicine at the Universite de Montreal. He is the Director of Research and Chief Scientific Officer of Sainte-Justine University Hospital.Dr. Moreau received his PhD in Microbiology and Immunology from the Universite de Montreal in 1993. He did a first postdoctoral training at the Protein Engineering Center of University of Liege, Belgium (1992-1993), followed by a second postdoctoral fellowship at the Shriners Hospital for Children in Montreal affiliated with McGill University (1993-1997). Dr. Moreau is an internationally recognized expert on molecular genetics of pediatric scoliosis and osteoarthritis. His discoveries led to multiple peer-reviewed papers, international conferences as guest speaker, several awards as well as 32 patents issued.

Protein engineering, Molecular genetics, Biomarkers

Chee Gee See is the Director of Personalised Medicine at Proteome Sciences, a company providing high end mass-spectrometry based biomarker discovery and clinical utility tools, uniquely positioned to engage with pharma partners in our quest for personalised medicines. CheeGee was previously the clinical Biomarker and Experimental Medicine Leader at Roche for 5 years. He was the BEML for the Phase III pivotal TOGA study where Herceptin was trialled for the new indication of gastric cancer. He was also a BEML for CVD, CNS and immunology so his range and awareness of disease areas and their clinical development challenges is both deep and broad. CheeGee also spent 11 years at GSK where he was a genetics expert covering 3 key therapeutic areas in preclinical research within Genetics Research Europe. Prior to industry, CheeGee spent 6 years in post-doctoral academia at the University of Birmingham and University College London, most notably in the Human Genome Mapping Project. CheeGee also has dual specialist expertise as a consultant in regulatory affairs and value-based drug pricing, reimbursement and market access. CheeGee looks forward to engaging with like-minded professionals during this conference.

Personalised Medicine, biomarkers, genetics

Leticia Cano identified a native citrullinated autoantigen for rheumatoid arthritis for her PhD dissertation. She did her postdoctoral training in the laboratory of Hank Fales at the National Institutes of Health, where she identified candidate biomarkers for Dermatomyositis, Juvenile Idiopathic Arthritis, and Systemic Lupus Erythematosus. As founder and president of Biomarker Profiles Corporation, she is interested in developing methods to increase the speed of biomarker discovery.

Biomarkers

Youhe Gao Professor Beijing Normal University. He received his MD from Peking Union Medical College, his Ph.D from University of Connecticut and postdoctoral training from Beth Israel Deaconess Medical Center Harvard Medical School. He was the professor of Department of Pathophysiology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences/ Peking Union Medical College from 2001-2014. His research interests include biomarker discovery in urine proteome, protein interaction and related bioinformatics

Biomarker discovery in urine proteome, Protein interaction and related bioinformatics

Sergey Suchkov graduated from Astrakhan State Medical University and was awarded with MD. In 1985, Suchkov obtained his Ph.D. He is the PhD student of the I.M. Sechenov Moscow Medical Academy and Institute of Medical Enzymology, USSR Academy of Medical Sciences, Moscow, Russia. In 2001, Suchkov finished the PostDoc Research Fellowship Program and maintained his Doctor Degree at the National Institute of Immunology, Russia. From 1987 through 1989, Dr. Suchkov was a senior Researcher, Lab of Developmental Immunology, Koltzov Institute of Developmental Biology, USSR Academy of Sciences to deal to developmental immunology. From 1989 through 1995, Dr. Suchkov was being a Head of the Lab of Clinical Immunology and Immunobiotechnology, Helmholtz Eye Research Institute in Moscow. From 1995 through 2004, Dr. Suchkov was being a Chairman of the Department for Clinical Immunology, Moscow Clinical Research Institute (MONIKI) and the Immunologist-in-Chief of the Moscow Regional Ministry of Health. At present, Dr Sergey Suchkov, MD, PhD, is Professor in Immunology, Department of Pathology, School for Pharmacy, I.M. Sechenov First Moscow State Medical University, Dean of the Department (Faculty) of The PPPM Development, and the First Vice-President of the University of World Business, Politics and Law and Secretary General, United Cultural Convention (UCC), Cambridge, UK.

Enzymology, biomarkers, cardiology, Immunology.

Charles J. Malemud received the Ph.D. from George Washington University in 1973 and completed postdoctoral studies at the State University of New York at Stony Brook in 1977. Since 1977, Dr. Malemud has been a member of the faculty at Case Western Reserve University School of Medicine where he is presently Professor of Medicine & Anatomy in the Division of Rheumatic Diseases and Senior Investigator in the Arthritis Research Laboratory. He has published more than 190 papers and reviews primarily in the field of chondrocyte biology. Professor Malemud is on the editorial board of several rheumatology, immunology and musculoskeletal journals and is Editor-in-Chief of the Journal of Clinical and Cellular Immunology. Close

Biology of the Musculoskeletal System, Intracellular Signal Transduction Pathways, Inflammation, Pro-inflammatory, Anti-Inflammatory &Anabolic Cytokines Apoptosis, Matrix Metalloproteinases, Osteoarthritis, Rheumatoid Arthritis, Fibromyalgia and Autoimmune Disorders

Dr A-Lien Lu-Chang completed her PhD from University of North Carolina at Chepel Hill and postdoctoral studies from Duke University School of Medicine with Dr. Paul Modrich (Nobel laureate in Chemistry in 2015). She is the Professor of Biochemistry and Molecular Biology at University of Maryland Medical School and a member of University of Maryland Greenebaum Comprehensive Cancer Center. She has published more than 63 peer-reviewed papers in reputed journals, holds a potent, and has been serving as an editorial board members of four journals.

My laboratory is studying the interplays among DNA repair, DNA replication, cell cycle checkpoint, transcription, and chromatin remodeling. We investigate the impact of their coordination on telomere integrity and carcinogensis. Our work highlights potential targets that can be exploited clinically for cancer therapies.

B.Sc and M.Sc. degrees from Allahabad University and Ph.D. from Gujarat University. Areas of Specialization: Life Sciences, Radiation Biology, Biotechnology, Biophysics and chemistry. Research Guide for Ph.D. students in many Universities of India. Successfully guided 41 Ph.D. students. Presently guiding 08 students. Published more than 280 research papers and proceeding papers in National and International Journals. Delivered more than 300 invited talks in Symposia and Conferences. Currently the Vice Chancellor of Nehru Gram Bharati University, Allahabad, India. Served as Head, Radiation Biology and Health Science Division and Senior Scientific Officer of Bhabha Atomic Research Center, Department of Atomic Energy, and Government of India. Chairman, Standing Selection Committee, Member, Trombay Scientific Council, BARC, Member, Health, Safety & Biomedical Group Board, Member, Committee of Atomic Energy Commission on Health and Environment Aspects of Uranium Mining at Jaduguda, Member, Core Expert Group on Chemical Disaster and Nuclear Disaster Management of National Disaster Management Authotrity of India (NDMA). Served as Chancellor's Nominee in Selection Committees of Padmashri Dr. D.Y. Patil Deemed University; Mumbai and West Bengal University of Technology, Kolkata and served as Expert on Selection Committees of IITs and several Universities in India.B.Sc and M.Sc. degrees from Allahabad University and Ph.D. from Gujarat University. Areas of Specialization: Life Sciences, Radiation Biology, Biotechnology, Biophysics and chemistry. Research Guide for Ph.D. students in many Universities of India. Successfully guided 41 Ph.D. students. Presently guiding 08 students. Published more than 280 research papers and proceeding papers in National and International Journals. Delivered more than 300 invited talks in Symposia and Conferences. Currently the Vice Chancellor of Nehru Gram Bharati University, Allahabad, India. Served as Head, Radiation Biology and Health Science Division and Senior Scientific Officer of Bhabha Atomic Research Center, Department of Atomic Energy, and Government of India. Chairman, Standing Selection Committee, Member, Trombay Scientific Council, BARC, Member, Health, Safety & Biomedical Group Board, Member, Committee of Atomic Energy Commission on Health and Environment Aspects of Uranium Mining at Jaduguda, Member, Core Expert Group on Chemical Disaster and Nuclear Disaster Management of National Disaster Management Authotrity of India (NDMA). Served as Chancellor's Nominee in Selection Committees of Padmashri Dr. D.Y. Patil Deemed University; Mumbai and West Bengal University of Technology, Kolkata and served as Expert on Selection Committees of IITs and several Universities in India.

Radiation Research, Biomarkers, Biophysics, Biotechnology